Qiu Xiaodi, Shi Yumeng, Han Xiaoyan, Hua Zhixiang, Lu Yi, Yang Jin
Eye Institute, Eye and Ear, Nose, and Throat, Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China.
Key Laboratory of Myopia, Ministry of Health, Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai 200031, China.
J Ophthalmol. 2021 Jan 20;2021:5960328. doi: 10.1155/2021/5960328. eCollection 2021.
A total of 57 cataract patients (57 eyes) with regular corneal astigmatism (≥2.57 D) were enrolled in this retrospective cohort study. Phacoemulsification with toric IOL implantation was performed for all patients. The uncorrected visual acuity (UCVA) and best corrected visual acuity (BCVA) were recorded before and one year after surgery, and statistical analysis of preoperative corneal astigmatism, postoperative residual astigmatism, aberrations, IOL rotation, and related factors was performed to evaluate the efficacy, safety, and stability of toric IOLs in correcting moderate-to-high corneal astigmatism.
One year after surgery, visual acuity was significantly improved compared with that before surgery (preoperative log MAR 0.87 ± 0.34 vs. postoperative log MAR 0.31 ± 0.26, < 0.001), and the self-reported spectacle independence rate was 68.42%. The total residual astigmatism was 1.18 ± 0.85 D, which was significantly less than the preoperative value (3.41 ± 0.99 D) ( < 0.001). The degree of toric IOL rotation was 4.93 ± 3.02°, and 54.39% of patients had a lens rotation of less than 5°. The IOLs of 5.26% (3 eyes) of patients rotated more than 10°, and these patients received glasses instead of undergoing IOL repositioning.
Toric IOL implantation provided optimal vision outcomes and low spectacle dependence during a one-year follow-up period. The results from our study show that toric IOL implantation is a safe and effective option for cataract patients with moderate-to-high corneal astigmatism.
本回顾性队列研究纳入了57例伴有规则角膜散光（≥2.57 D）的白内障患者（57只眼）。所有患者均接受了白内障超声乳化联合散光人工晶状体植入术。记录手术前及术后1年的未矫正视力（UCVA）和最佳矫正视力（BCVA），并对术前角膜散光、术后残余散光、像差、人工晶状体旋转及相关因素进行统计分析，以评估散光人工晶状体矫正中高度角膜散光的有效性、安全性和稳定性。
术后1年，视力较术前显著提高（术前logMAR 0.87±0.34 vs.术后logMAR 0.31±0.26，<0.001），自我报告的脱镜率为68.42%。总残余散光为1.18±0.85 D，显著低于术前值（3.41±0.99 D）（<0.001）。散光人工晶状体的旋转度数为4.93±3.02°，54.39%的患者晶状体旋转小于5°。5.26%（3只眼）患者的人工晶状体旋转超过10°，这些患者佩戴眼镜而非接受人工晶状体重新定位。
在1年的随访期内，散光人工晶状体植入提供了最佳的视力结果和较低的眼镜依赖。我们的研究结果表明，散光人工晶状体植入对于伴有中高度角膜散光的白内障患者是一种安全有效的选择。
